Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 |
Mar. 31, 2024 |
Mar. 31, 2023 |
Dec. 31, 2023 |
|
| Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||||
| Estimated fair value of equity securities | $ 45,616 | $ 41,937 | ||
| Unrealized gain (loss) on equity securities | $ 3,679 | $ (6,992) | ||
| Vaxcyte, Inc. | Vaxcyte Common Stock | ||||
| Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||||
| Number of shares held | 667,780 | 667,780 | ||
| Estimated fair value of equity securities | $ 45,600 | $ 41,900 | ||
| Unrealized gain (loss) on equity securities | $ 3,700 | $ (7,000) | ||
| Blackstone Life Sciences | Royalty | 2015 License Agreement | ||||
| Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||||
| Revenue interest percentage | 4.00% | 4.00% | ||